PMID- 26707788
OWN - NLM
STAT- MEDLINE
DCOM- 20161019
LR  - 20220408
IS  - 1573-2592 (Electronic)
IS  - 0271-9142 (Linking)
VI  - 36
IP  - 1
DP  - 2016 Jan
TI  - Angioedema Triggered by Medication Blocking the Renin/Angiotensin System: 
      Retrospective Study Using the French National Pharmacovigilance Database.
PG  - 95-102
LID - 10.1007/s10875-015-0228-3 [doi]
AB  - INTRODUCTION: Bradykinin-mediated angioedema (AE) is a rare side effect of some 
      medications, including angiotensin converting enzyme inhibitors (ACEi) and 
      angiotensin receptor blockers (ARB). In France, side-effects to treatments are 
      reported to the national pharmacovigilance database. METHODS: The national MedDRA 
      database was searched using the term "angioedema". Patients were included if they 
      met the clinical criteria corresponding to bradykinin-mediated AE, if their 
      C1-inhibitor levels were normal, and if they were treated with an ACEi or an ARB. 
      RESULTS: 7998 cases of AE were reported between 1994 and 2013. Among these, 112 
      met the criteria for bradykinin-mediated AE with normal C1-inhibitor levels. On 
      the 112 drug-AE, patients were treated with an ARB in 21% of cases (24 patients), 
      or an ACEi in 77% of cases (88 patients), in combination with another treatment 
      in 17 cases (mTORi for 3 patients, iDPP-4 for 1 patient, hormonal treatment for 7 
      patients). ENT involvement was reported in 90% of cases (tongue: 48.2%, larynx: 
      23.2%). The median duration of treatment before the first attack was 720 days, 
      and the mean duration of attacks was 36.6 h. Forty-one percent (19/46) of 
      patients relapsed after discontinuing treatment. CONCLUSION: Angioedema triggered 
      by medication blocking the renin/angiotensin system is rare but potentially 
      severe, with a high risk of recurrence despite cessation of the causative drug.
FAU - Faisant, Charles
AU  - Faisant C
AD  - Internal Medicine Department, Grenoble University Hospital, Grenoble, France. 
      cfaisant@chu-grenoble.fr.
AD  - Grenoble Alps University, Grenoble, France. cfaisant@chu-grenoble.fr.
AD  - Clinique Universitaire de Medecine Interne, CHU de Grenoble, Hopital Michallon 
      CS10217, 38043, Grenoble, Cedex 09, France. cfaisant@chu-grenoble.fr.
FAU - Armengol, Guillaume
AU  - Armengol G
AD  - Internal Medicine Department, Rouen University Hospital, Rouen, France.
FAU - Bouillet, Laurence
AU  - Bouillet L
AD  - Internal Medicine Department, Grenoble University Hospital, Grenoble, France.
AD  - Grenoble Alps University, Grenoble, France.
AD  - French National Reference Centre for Angioedema (CREAK), Grenoble, France.
AD  - Inserm-UJF-CEA-CNRS Unit 1036, IRTSV, CEA Grenoble, Grenoble, France.
FAU - Boccon-Gibod, Isabelle
AU  - Boccon-Gibod I
AD  - Internal Medicine Department, Grenoble University Hospital, Grenoble, France.
AD  - French National Reference Centre for Angioedema (CREAK), Grenoble, France.
FAU - Villier, Celine
AU  - Villier C
AD  - Pharmacovigilance Department, Grenoble University Hospital, Grenoble, France.
FAU - Levesque, Herve
AU  - Levesque H
AD  - Internal Medicine Department, Rouen University Hospital, Rouen, France.
AD  - Inserm U1096, Rouen, France.
FAU - Cottin, Judith
AU  - Cottin J
AD  - Pharmacovigilance Department, Lyon University Hospital, Lyon, France.
FAU - Massy, Nathalie
AU  - Massy N
AD  - Pharmacovigilance Department, Rouen University Hospital, Rouen, France.
FAU - Benhamou, Ygal
AU  - Benhamou Y
AD  - Internal Medicine Department, Rouen University Hospital, Rouen, France.
AD  - Inserm U1096, Rouen, France.
LA  - eng
PT  - Journal Article
DEP - 20151228
PL  - Netherlands
TA  - J Clin Immunol
JT  - Journal of clinical immunology
JID - 8102137
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Aged
MH  - Angioedema/chemically induced/*epidemiology
MH  - Angiotensin-Converting Enzyme Inhibitors/*administration & dosage/adverse effects
MH  - Bradykinin/*administration & dosage/adverse effects
MH  - Databases, Factual
MH  - Female
MH  - France
MH  - Humans
MH  - Male
MH  - Pharmacovigilance
MH  - Recurrence
MH  - Renin-Angiotensin System/drug effects
MH  - Retrospective Studies
MH  - Withholding Treatment
OTO - NOTNLM
OT  - Angioedema
OT  - angiotensin II antagonist
OT  - angiotensin converting enzyme inhibitor
OT  - bradykinin
EDAT- 2015/12/29 06:00
MHDA- 2016/12/30 06:00
CRDT- 2015/12/29 06:00
PHST- 2015/07/07 00:00 [received]
PHST- 2015/12/14 00:00 [accepted]
PHST- 2015/12/29 06:00 [entrez]
PHST- 2015/12/29 06:00 [pubmed]
PHST- 2016/12/30 06:00 [medline]
AID - 10.1007/s10875-015-0228-3 [pii]
AID - 10.1007/s10875-015-0228-3 [doi]
PST - ppublish
SO  - J Clin Immunol. 2016 Jan;36(1):95-102. doi: 10.1007/s10875-015-0228-3. Epub 2015 
      Dec 28.